Chairman of the board and incoming CEO of ADDvise divests shares of series A and acquires shares of series B

The chairman of the board and incoming CEO Staffan Torstensson has today, privately and through companies, divested 610,000 shares of series A to Kenneth Lindqvist, one of the major shareholders of ADDvise, privately and through companies. The total purchase price for the shares amounted to SEK 9,150,000. In conjunction with the divestment of the shares of series A, Staffan Torstensson has acquired 1,500,000 shares of series B in ADDvise at a price of SEK 5.86 per share.

After the transactions, Staffan Torstensson’s holdings, privately and through companies, will amount to 4,816,660 shares of series B.

The transactions will be reported to the Swedish Financial Supervisory in accordance with applicable regulations.

For further information, please contact:

Staffan Torstensson, chairman of the board of directors

+46 (0) 70-433 20 19

About ADDvise

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company's Certified Adviser. More information is available at www.addvisegroup.com.